Tali Voloshin Sela
About Tali Voloshin Sela
Tali Voloshin Sela is the Director of Preclinical Research at Novocure in Israel, with over nine years of experience at the company. She holds a Ph.D. in Biomedical Sciences Molecular Pharmacology from Technion - Israel Institute of Technology.
Director of Preclinical Research at Novocure
Tali Voloshin Sela currently serves as the Director of Preclinical Research at Novocure in Israel. In this role, she oversees research activities focused on the preclinical development of novel cancer treatments. Since 2021, she has been responsible for leading a team and managing projects aimed at advancing the company's cancer treatment technologies.
Career Progression at Novocure
Tali Voloshin Sela has been a part of Novocure for over 9 years. She started her career at the company in 2014 as a Senior Scientist. After four years in this position, she was promoted to Associate Director of Preclinical Research in 2018, a role she held for three years. In 2021, she advanced to her current position as Director of Preclinical Research.
Educational Background in Biomedical Sciences
Tali Voloshin Sela holds a Doctor of Philosophy (Ph.D.) in Biomedical Sciences Molecular Pharmacology from the Technion - Israel Institute of Technology, which she completed over five years from 2009 to 2014. Her academic journey also includes a Master of Science (M.Sc.) in Molecular Immunology from the same institution, completed from 2007 to 2009, and a Bachelor of Science (B.Sc.) in Biology, achieved from 2004 to 2007.
Academic Research Experience
Throughout her academic career, Tali Voloshin Sela has specialized in various aspects of biological and biomedical sciences. Her research experience is rooted in her studies at the Technion - Israel Institute of Technology, where she engaged in in-depth exploration of molecular pharmacology and immunology. Her Ph.D. and Master's studies provided her with a robust foundation in these fields, which she has put to use in her professional career at Novocure.